Brief: Nuwellis’ Strategic Partner, Seastar Medical, Receives FDA Approvable Letter For Pediatric Selective Cytopheretic Device
31/10/2023 12:08
Oct 31 (Reuters) -
* NUWELLIS’ STRATEGIC PARTNER, SEASTAR MEDICAL, RECEIVES FDA
APPROVABLE LETTER FOR ITS PEDIATRIC SELECTIVE CYTOPHERETIC
DEVICE
Source text for Eikon: ID:nGNX3vGfk7
Further company coverage: ICU.O
Recent news on SeaStar Medical Holding
See all newsBrief: FDA Grants Seastar Medical Breakthrough Device Designation For Its Scd Therapy For The Treatment Of Hyperinflammation In Adult Patients With Sepsis Or A Septic Condition
SeaStar Medical Holding Corp reports results for the quarter ended June 30 - Earnings Summary
SeaStar Medical Q2 revenue jumps 82% on QUELIMMUNE demand
Brief: SeaStar Medical Q2 EPS USD -0.91
SeaStar Medical Holding Corp expected to post a loss of 97 cents a share - Earnings Preview